Article
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Cancer investigation - 1 Jan 2015
Pagnano Katia Borgia Barbosa, Bendit Israel, Boquimpani Carla, De Souza Carmino Antonio, Miranda Eliana C M, Zalcberg Ilana, Larripa Irene, Nardinelli Luciana, Silveira Rosana Antunes, Fogliatto Laura, Spector Nelson, Funke Vaneuza, Pasquini Ricardo, Hungria Vania, Chiattone Carlos Sérgio, Clementino Nelma, Conchon Monika, Moiraghi Elena Beatriz, Lopez Jose Luis, Pavlovsky Carolina, Pavlovsky Miguel A, Cervera Eduardo E, Meillon Luis Antonio, Simões Belinda, Hamerschlak Nelson, Bozzano Alicia Helena Magarinos, Mayta Ernesto, Cortes Jorge, Bengió Raquel M
Abstract excerpt
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.